Journal of Clinical Oncology
Articles in this Issue
A phase 1 study of PHST001, an anti-CD24 monoclonal antibody, in adult patients with advanced relapsed and/or refractory solid tumors.
TPS2685 Background: Macrophages are the most abundant immune cells in tumors and can directly phagocytose tumor cells and...
Treatment patterns, acute-care utilization, and clinical outcomes among patients with lung cancer and sickle cell disease: A multicenter propensity score–matched real-world analysis.
e20706 Background: Sickle cell disease (SCD) is associated with chronic organ dysfunction, heightened thrombo inflammatory...
Central nervous system metastases in hereditary breast cancer according to germline pathogenic variants: A real-world cohort study.
2035 Background: Hereditary breast cancer (HBC) accounts for approximately 5–10% of cases and involves pathogenic germline...
Impact of concomitant <i>NPM1</i> mutations on genomic and transcriptomic patterns of <i>PTPN11</i> -mutant myeloid leukemias.
6532 Background: PTPN11 mutations are associated with worse treatment outcomes in acute myeloid leukem...
Activating MPN patients through empowering, patient-centered education.
6577 Background: Patients living with myeloproliferative neoplasms (MPNs) face complex disease management, evolving treatm...
Uncertainty-aware AI triage for LUAD histologic subtyping: Flagging cases for expert review.
e20018 Background: AI-assisted histological subtyping of lung adenocarcinoma (LUAD) shows promise but imperfect accuracy i...
Improving internal medicine residents’ confidence in oncology goals-of-care conversations.
TPS9047 Background: Internal medicine (IM) residents frequently participate in goals-of-care (GOC) discussions for patient...
Treatment-emergent thyroid disorders and outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer: A real-world study.
e13125 Background: Pembrolizumab+chemotherapy (P+C) is a standard first-line treatment for PD-L1 positive metastatic tripl...
Inequality of access to breast reconstruction in Brazil: An ecological study.
e13742 Background: Breast reconstruction (BR) is an important step in breast cancer treatment, and several authors have re...
Cardiovascular disease incidence in women with early-onset breast cancer.
12018 Background: Early-onset breast cancer (BC) before age 40 is generally associated with advanced stage at diagnosis an...
Mapping the exhausted and tolerized myeloid populations in the glioblastoma tumor microenvironment.
2066 Background: Glioblastoma (GBM) is a highly malignant brain tumor characterized by an immunosuppressive microenvironme...
Early risk stratification for sarcopenia in a pan-cancer cohort using quantile regression forests on handgrip strength.
e13585 Background: Sarcopenia, characterized by loss of muscle mass, strength, and physical function, is associated with p...
IvoLoC: A phase II trial of ivonescimab (IVO) in endocrine-refractory hormone receptor (HR)–positive or triple-negative (TN) metastatic invasive lobular carcinoma (mILC).
TPS1166 Background: ILC accounts for approximately 10–15% of breast cancers and is predominantly hormone receptor–positive...
First-in-human dose escalation trial of an engineered salmonella delivering L-methioninase in advanced bone and soft tissue sarcomas.
11530 Background: Advanced bone and soft-tissue sarcomas have limited treatment options. Tumor-selective methionine depend...
Ciltacabtagene autoleucel in lenalidomide-refractory multiple myeloma responding to bridging therapy: CARTITUDE-4 cytogenetic subgroup analysis.
7536 Background: CARTITUDE-4 (NCT04181827) showed significant overall (OS) and progression-free survival (PFS) benefits of...
Effect of eligibility burden on survival time in pancreatic cancer clinical trials.
e23023 Background: Pancreatic ductal adenocarcinoma (PDAC) has median survival measured in months, yet the survival time c...
Role of microbiota in response to treatment in anal squamous cell carcinoma.
3518 Background: Anal squamous cell carcinoma (ASCC) is a rare tumor whose management and treatment have not changed since...
Real-world outcomes of polatuzumab vedotin plus R-CHP versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma: A propensity-matched analysis.
e19087 Background: Polatuzumab vedotin plus R-CHP (Pola-R-CHP) was approved as frontline therapy for diffuse large B-cell...
Artificial intelligence–powered spatial analysis of endothelial cells and tumor-infiltrating lymphocytes to predict response to axitinib in adenoid cystic carcinoma.
6122 Background: Despite the limited systemic options for adenoid cystic carcinoma (ACC), VEGFR inhibitors remain a clinic...
Comparative analysis of national cancer policy among low-income, low-middle-income, and high-middle-income countries.
e23045 Background: Despite lower incidence rates, under-resources and lower income countries bear a disproportionately hig...
Efficacy and safety of immune checkpoint inhibitors in advanced non–small cell lung cancer: A systematic review and meta-analysis of randomized trials.
e20621 Background: Immune checkpoint inhibitors (ICIs) are standard first line therapy for advanced non small cell lung ca...
Long-term outcomes with addition of inotuzumab ozogamicin to HCVAD and sequential blinatumomab in adults with newly diagnosed B-ALL.
6515 Background: Despite high remission rates with intensive chemotherapy and blinatumomab (blina) in newly diagnosed (ND)...
An international phase III randomized, double-blind, double-dummy trial comparing duloxetine and pregabalin for opioid-refractory neuropathic cancer pain.
12013 Background: Management of neuropathic cancer pain (NCP) refractory to standard-dose opioids remains a major clinical...
Developing harmonized tumor microenvironment subtypes for patient stratification in clinical trials.
3120 Background: Accurate patient stratification by tumor microenvironment (TME) is critical for optimizing immunotherapy...
Intersectional analysis of race/ethnicity, geography, and socioeconomic status on colorectal cancer screening utilization and stage at diagnosis: A SEER analysis, 2016-2021.
e15714 Background: Despite effective screening modalities, colorectal cancer (CRC) remains the second leading cause of can...